Rafael Bejar - 19 Jan 2023 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)

Role
Sr. VP, Chief Medical Officer
Signature
/s/ Fletcher Payne as attorney-in-fact for Rafael Bejar
Issuer symbol
APTOF
Transactions as of
19 Jan 2023
Net transactions value
$0
Form type
4
Filing time
23 Jan 2023, 18:50:03 UTC
Previous filing
20 Jan 2022
Next filing
07 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APTO Common Shares Award $0 +100,000 +1000% $0.000000 110,000 19 Jan 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APTO Employee Stock Option Award $0 +200,000 $0.000000 200,000 19 Jan 2023 Common Shares 200,000 $0.6600 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fifty percent (50%) of the options vest on January 19, 2024; the remaining fifty percent (50%) vest as follows: one-third (1/3) on January 19, 2025; one-third (1/3) on January 19, 2026; and one-third on January 19, 2027.